Omburtamab Biosimilar
REQUEST MORE INFO
Catalogue No: abx831492
Price:
US$391.50
(Size: 1 mg)
Orders to United States ship from United States
Add to Cart
Buy It Now
GET A QUOTE
Documents
Datasheet SDS
Omburtamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD276/B7-H3/B7RP-2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Omburtamab is a monoclonal antibody that targets the B7-H3 antigen expressed in a variety of human solid tumors. Omburtamab (alias: 8H9, former name: Burtomab) is a monoclonal antibody that is linked to a radioisotope and can bind to the B7-H3 antigen on the surface of neuroblastoma cells. It is injected directly into the cerebrospinal fluid to bypass the blood-brain barrier and accurately target neuroblastoma in the central nervous system to avoid damage to other tissues (such as learning disabilities and developmental delays often caused by conventional radiotherapy outside the brain).
Research Articles on CD276/B7-H3/B7RP-2
| Target | CD276/B7-H3/B7RP-2 |
| Research Area | Biosimilars |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA |
| Host | Mouse |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG1 Kappa |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles. |
| Shelf Life | 12 months. |
| Buffer | 0.01 M PBS, pH 7.4. |
| CAS Number | 1895083-75-6 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 5-10 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
